PyrAmes develops wearable bands (Boppli and Bosimi) designed to provide noninvasive, continuous blood pressure monitoring for infants in the NICU and women during and after pregnancy. The company’s lead product, Boppli, has received Breakthrough Device Designation from the U.S. Food and Drug Administration. PyrAmes is further developing its proprietary technology to monitor blood pressure in women at risk of hypertensive disorders of pregnancy, such as gestational hypertension and preeclampsia. PyrAmes received an investment from March of Dimes to support development and commercialization of its maternal and pediatric monitoring products. Its first commercial product, Boppli, is expected to be available after FDA 510(k) clearance anticipated in 2023, and products based on the technology are still under development and not yet cleared for distribution. The company emphasizes safer alternatives to arterial lines and more convenient continuous monitoring versus standard cuffs. PyrAmes is a development-stage digital health company focused on continuous, wireless and non-invasive blood pressure monitoring. Its lead product, Boppli™, is a wireless sensor band designed to continuously measure blood pressure for infants in the neonatal intensive care unit (NICU) without the risks of an invasive arterial catheter. The FDA has granted Breakthrough Device Designation for Boppli. The company plans follow-on products for adults in inpatient and at-home settings. Proceeds from the announced financing will be used for pilot-scale manufacturing, clinical validation studies, and regulatory agency reviews. Xina Quan, Ph.D., is Co‑Founder and CEO, and the company is based in Cupertino, Calif.

Total raised

$6M

Funding rounds

2

Latest round

Series A

Latest activity

Apr 2021